Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where George F. Lundell is active.

Publication


Featured researches published by George F. Lundell.


Journal of Heterocyclic Chemistry | 1977

N-trimethylsilylpyrroles as dienes in the synthesis of 1,4-dihydronaphthalen-1,4-imines and isoindoles†

Paul S. Anderson; Marcia E. Christy; Edward L. Engelhardt; George F. Lundell; C. S. Ponticello

A convenient, general synthetic method for 1,4-dihydronaphthaIen-1,4-imines via the Diels-Alder addition of benzyne to N-trimethylsilylpyrrole is described. The N-trimethylsilyl protecting group protected the product from secondary benzyne reactions and was easily removed. The use of a 1,3-dipolar reagent to convert 1,4-dihydronaphthalen-1,4-imines to isoindoles via a retro-Diels-Alder sequence is illustrated.


Archive | 1990

Potent and Selective Oxytocin Antagonists Obtained by Chemical Modification of a Streptomyces Silvensis Derived Cyclic Hexapeptide and by Total Synthesis

Mark G. Bock; Robert M. DiPardo; Peter D. Williams; R. D. Tung; J. M. Erb; Norman P. Gould; Willie L. Whitter; Debra S. Perlow; George F. Lundell; Richard G. Ball; Douglas J. Pettibone; B. V. Clineschmidt; Daniel F. Veber; Roger M. Freidinger

Oxytocin (OT) is a neurohypophyseal hormone which has an important function in parturition.1 There is considerable evidence that the uterotonic action of OT and its stimulation of uterine prostaglandin release combine to initiate labor.2,3 Additionally, OT mediates the postpartum function of contracting the mammary myoepithelium to elicit milk letdown4 and has also recently been implicated as a key element in preterm labor.5,6 Attempts to further delineate these OT connected events have provided the impetus to discover agents which interact selectively and competitively at the OT receptor. Such compounds are invaluable in determining the physiological and pathophysiological role of OT and its close structurally related hormone, arginine vasopressin (AVP). Additional interest derives from the prospect of their use as novel therapeutic agents.


Journal of Medicinal Chemistry | 1988

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

Ben E. Evans; Kenneth E. Rittle; Mark G. Bock; Robert M. DiPardo; Roger M. Freidinger; Willie L. Whitter; George F. Lundell; Daniel F. Veber; Paul S. Anderson; Raymond S.L. Chang; Victor J. Lotti; D. J. Cerino; Tsing-Bau Chen; P. J. Kling; K. A. Kunkel; James P. Springer; Jordan Hirshfield


Journal of Medicinal Chemistry | 1992

Orally active, nonpeptide oxytocin antagonists

Ben E. Evans; James L. Leighton; Kenneth E. Rittle; Kevin F. Gilbert; George F. Lundell; Norman P. Gould; Doug W. Hobbs; Robert M. DiPardo; Daniel F. Veber; Douglas J. Pettibone; Bradley V. Clineschmidt; Paul S. Anderson; Roger M. Freidinger


Journal of Medicinal Chemistry | 2004

Discovery and Evaluation of Potent P1 Aryl Heterocycle-Based Thrombin Inhibitors

Mary Beth Young; James C. Barrow; Kristen L. Glass; George F. Lundell; Christina L. Newton; Janetta M. Pellicore; Kenneth E. Rittle; Harold G. Selnick; Kenneth J. Stauffer; Joseph P. Vacca; Peter D. Williams; Dennis Bohn; Franklin C. Clayton; Jacquelynn J. Cook; Julie A. Krueger; Lawrence C. Kuo; S. Dale Lewis; Bobby J. Lucas; Daniel R. McMasters; Cynthia Miller-Stein; Beth Pietrak; Audrey A. Wallace; Rebecca B. White; Bradley K. Wong; Youwei Yan; Philippe G. Nantermet


Endocrinology | 1989

A Structurally Unique, Potent, and Selective Oxytocin Antagonist Derived from Streptomyces silvensis

Douglas J. Pettibone; Bradley V. Clineschmidt; Paul S. Anderson; Roger M. Freidinger; George F. Lundell; Lawrence R. Koupal; Cheryl D. Schwartz; Joanne M. Williamson; Michael A. Goetz; Otto D. Hensens; Jerrold M. Liesch; James P. Springer


Journal of Medicinal Chemistry | 1984

Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists

Jones Jh; Paul S. Anderson; John J. Baldwin; Bradley V. Clineschmidt; David E. McClure; George F. Lundell; Randall Wc; Martin Ge; Williams M; Jordan Hirshfield


Journal of Medicinal Chemistry | 1979

Symbiotic approach to drug design: antihypertensive .beta.-adrenergic blocking agents

John J. Baldwin; William C. Lumma; George F. Lundell; Gerald S. Ponticello; Andrew W. Raab; Edward L. Engelhardt; Ralph Hirschmann; Charles S. Sweet; Alexander Scriabine


Journal of Medicinal Chemistry | 1992

Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product

Peter D. Williams; Mark G. Bock; Tung Rd; Garsky Vm; Debra S. Perlow; Jill M. Erb; George F. Lundell; Norman P. Gould; Willie L. Whitter; Hoffman Jb


Journal of Medicinal Chemistry | 1993

Nanomolar-affinity, non-peptide oxytocin receptor antagonists

Ben E. Evans; George F. Lundell; Kevin F. Gilbert; Mark G. Bock; Kenneth E. Rittle; Leigh Anne Carroll; Peter D. Williams; Joseph M. Pawluczyk; James L. Leighton

Collaboration


Dive into the George F. Lundell's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Douglas J. Pettibone

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Kevin F. Gilbert

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Doug W. Hobbs

United States Military Academy

View shared research outputs
Researchain Logo
Decentralizing Knowledge